VIP is secreted by neurons in the esophagus where it relaxes the lower sphincter muscles, so we believe there is compelling evidence in favor of human clinical trials of anti-VIP or VIP receptor antagonist therapy to both reduce esophageal eosinophilia and improve esophageal motility dysfunction in EoE and even in GERD. Here, VIP is linked to eosinophilic esophagitis.